Difference between revisions of "Pyruvate kinase deficiency"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m |
||
| Line 8: | Line 8: | ||
*'''2024:''' Al-Samkari et al. [https://doi.org/10.1016/s2352-3026(23)00377-0 Diagnosis and management of pyruvate kinase deficiency: international expert guidelines] [https://pubmed.ncbi.nlm.nih.gov/38330977/ PubMed] | *'''2024:''' Al-Samkari et al. [https://doi.org/10.1016/s2352-3026(23)00377-0 Diagnosis and management of pyruvate kinase deficiency: international expert guidelines] [https://pubmed.ncbi.nlm.nih.gov/38330977/ PubMed] | ||
| + | [[Category:Pyruvate kinase deficiency regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Hemolytic process]] | [[Category:Hemolytic process]] | ||
Revision as of 13:24, 4 March 2024
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
Guidelines
International expert guidelines
- 2024: Al-Samkari et al. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines PubMed